Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Atara Biotherapeutics Q3 2026 Results: Net Loss of $2.23M, Loss Narrows

Atara Biotherapeutics reported a decrease in cash and cash equivalents to $4.1 million as of September 30, 2026, down from $8.5 million at year-end 2025. The company is currently reviewing strategic alternatives and warns that it will require substantial near-term financing to continue operations, raising concerns about its ability to fund planned operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.23.5
Profit before tax-2.2-4.3
Net income-2.2-4.3
EPS (diluted, $ a share)$-0.15$-0.32

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-64.6%
Operating margin-242.6%
Source

10-Q filed with the SEC, NASDAQ: ATRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Atara Biotherapeutics, Inc.: key numbers

Share price
$6.50Close, Nov 17
Market cap
$66.2M
Shares outstanding
10.19MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Atara Biotherapeutics, Inc.

All →
4:11 PM ET 8-K
Financial Results

Atara Biotherapeutics Financial Results

Atara Biotherapeutics reported Q3 2026 financial results, highlighting a significant 83% year-over-year reduction in operating expenses and a net loss of $2.2 million. The company is focused on the FDA's March 31, 2027, PDUFA date for tab-cel, which if approved would trigger a $31 million milestone payment from Pierre Fabre Laboratories.

“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome. We continue to believe in tab-cel’s significant commercial potential in the U.S. In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.”

Cokey Nguyen, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.